Advances & Considerations in Pharmacotherapy of Attention-deficit/hyperactivitydisorder (ADHD)

  • Posted on: 31 March 2017
  • By: admin

 

Magazine Home


April 2017 ARTICLE LIST >>

PharmaTutor (April - 2017)

 

ISSN: 2347 - 7881
(Volume 5, Issue 4)

 

Received On: 14/12/2016; Accepted On: 04/01/2017; Published On: 01/04/2017

 

AUTHORS:
Noorul Hasan*, Mohd. Mujahid, Badruddeen, Nesar Ahmad, Shahla Parveen,Shaikh Zohrameena, Zafar Khan
Faculty of Pharmacy,
 Integral University,
Lucknow, U.P., India
*noorulkhan999@gmail.com

 

 

ABSTRACT:
Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral condition primarily affecting children but regularly persisting into adolescence and adulthood. The symptoms must present in multiple settings ie home, school, work, be inappropriate for developmental level and interfere with the individual’s level of functioning, social development, learning processes, and quality of life. There are three presentations of ADHD i.e. inattentive, hyperactive and combined. There is a substantial pharmacopoeia available for safe and effective treatment of ADHD. CNS stimulants like methylphenidate, amphetamine are recommended as first-line medication therapy for children.

 

 

How to cite this article: Hasan N, Mujahid M, Badruddeen, Ahmad N, Parveen S, Zohrameena S, Khan Z;Advances & Considerations in Pharmacotherapy of Attention-deficit / hyperactivity disorder (ADHD); PharmaTutor; 2017; 5(4);28-37

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML